Biotech company pushes development of hydrogel-based wound product

10/8/2013 | PharmaBiz.com (India)

Biotechnology company BioTime has begun pre-approval testing of a wound dressing based on cross-linked thiol-modified hyaluronan and thiol-modified gelatin. The product maintains a moist wound bed, and a biodegradable matrix serves as a scaffold for cellular infiltration and capillary growth. If approved, the product may provide a foundation for bioactive wound care products that deliver biological factors or cells.

View Full Article in:

PharmaBiz.com (India)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Food & Drug Associate
Confidential
Washington, D.C., DC